Australian ‘Uptake Drivers’ For Boosting Biosimilar Prescribing Start With Etanercept
Executive Summary
Biosimilars are being given a boost in Australia through the use of “uptake drivers” to encourage doctors to prescribe a biosimilars in preference to the reference product. The first product involved is etanercept.
You may also be interested in...
Australia: Easier & Faster Mechanisms To Drive Biosimilars Uptake
It will soon become easier to prescribe a number of medicines for rheumatoid arthritis and plaque psoriasis in Australia.
Australia: Easier & Faster Mechanisms To Drive Biosimilars Uptake
It will soon become easier to prescribe a number of medicines for rheumatoid arthritis and plaque psoriasis in Australia.
Roche Court Win Keeps Sandoz' Biosimilar Rituximab Off Australian Market For A Year
A decision by an Australian court to prevent Sandoz from launching its biosimilar rituximab in Australia until August 2019 means a continued monopoly for Roche and lost sales for Sandoz, while the healthcare system misses out on significant potential savings.